<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144700">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02016885</url>
  </required_header>
  <id_info>
    <org_study_id>DRM04-HH01</org_study_id>
    <nct_id>NCT02016885</nct_id>
  </id_info>
  <brief_title>A Dose-Ranging Study of the Effect of DRM04B in Subjects With Axillary Hyperhidrosis</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Vehicle Controlled, Dose-Ranging Study of the Effect of DRM04B in Subjects With Axillary Hyperhidrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermira, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of DRM04B compared to
      vehicle for the treatment of axillary hyperhidrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, vehicle controlled, dose-ranging study enrolling subjects with
      axillary hyperhidrosis and designed to assess the safety and efficacy of four doses of
      DRM04B compared to vehicle. There are 5 arms in this study.

      Efficacy will be assessed through the Hyperhidrosis Disease Severity Score (HDSS),
      Dermatology Life Quality Index (DLQI) and a gravimetric assessment of sweat production.

      Safety will be assessed, at specified times during the study, through adverse events, local
      skin responses, serum chemistry and hematology laboratory testing, ECGs, physical
      examination and vital signs.

      PK samples will be taken from 20 to 30 subjects participating in the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of subjects who have a minimum 2-grade improvement in HDSS from baseline.</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in the gravimetrically measured sweat production.</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have a minimum 1-grade improvement in HDSS.</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in the gravimetrically measured sweat.</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have a minimum 1-grade improvement in HDSS.</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Not provided.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>DRM04B, 1.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRM04B, 1.0%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DRM04B, 2.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRM04B, 2.0%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DRM04B, 3.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRM04B, 3.0%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DRM04B, 4.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRM04B, 4.0%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRM04B, 1.0%</intervention_name>
    <arm_group_label>DRM04B, 1.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRM04B, 2.0%</intervention_name>
    <arm_group_label>DRM04B, 2.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRM04B, 3.0%</intervention_name>
    <arm_group_label>DRM04B, 3.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRM04B, 4.0%</intervention_name>
    <arm_group_label>DRM04B, 4.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 years of age or older.

          -  Primary, axillary hyperhidrosis of at least 6 months duration.

          -  A Hyperhidrosis Disease Severity Score (HDSS) of 3or 4.

          -  A gravimetric measurement of sweat production of at least 50 mg over 5 minutes in
             each axilla (total of 100 mg) while at rest at room temperature.

          -  Male or non-pregnant, non-lactating females.

        Exclusion Criteria:

          -  Prior surgical procedure for hyperhidrosis.

          -  Any prior treatment with an axillary anti-hyperhidrosis medical device (approved or
             investigational)

          -  Prior treatment with botulinum toxin for axillary hyperhidrosis within 1 year.

          -  Treatment with cholinergic, serotonergic antagonists, and dopamine partial agonists
             thought to relieve antidepressant-induced hyperhidrosis. Treatment with
             psychotherapeutic medications for less than 4 months prior to study enrollment. -
             Treatment with topical or systemic anticholinergics, adrenergic agonists (clonidine),
             or beta-blockers within 4 weeks prior to enrollment.

          -  Prior axillary treatment with axillary iontophoresis within 4 weeks.

          -  Axillary use of nonprescription or prescription antiperspirants within 2 weeks of
             study enrollment.

          -  Known history of a condition that may cause secondary hyperhidrosis.

          -  Known history of Sj√∂gren's syndrome or Sicca  syndrome.

          -  Abnormal findings on screening ECG deemed clinically significant by the Investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynne M Deans, MT</last_name>
    <role>Study Director</role>
    <affiliation>Dermira, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie Reed</last_name>
    <phone>201-587-0500</phone>
    <phone_ext>3362</phone_ext>
    <email>ereed@tklresearch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Manley, LPN, CCRC</last_name>
      <phone>501-620-4449</phone>
      <email>lmanley@burkepharmaceutical.com</email>
    </contact>
    <investigator>
      <last_name>Dowling B Stough, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gary M. Petrus, MD, PA</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Kim Rodgers</last_name>
      <phone>501-614-3052</phone>
      <email>kim@drpetrus.com</email>
    </contact>
    <investigator>
      <last_name>Gary M Petrus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Dermatology &amp; Clinical Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Brusch</last_name>
      <phone>760-203-3839</phone>
      <email>donnab@cdcrinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Stacy Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center For Dermatology Clinical Research</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galyna Cavallaro, CRC</last_name>
      <phone>510-797-0110</phone>
      <email>galynac@centerforderm.com</email>
    </contact>
    <investigator>
      <last_name>Sunil S Dhawan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Academic Dermatology Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annika Grant</last_name>
      <phone>305-324-2110</phone>
      <phone_ext>201</phone_ext>
      <email>annika@fadcenter.com</email>
    </contact>
    <investigator>
      <last_name>Francisco A Kerdel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kenneth R. Beer, MD, PA</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Dunn, RN, BSN</last_name>
      <phone>561-655-9055</phone>
      <email>mdunn@palmbeachcosmetic.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth Beer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shideler Clinical Research Center</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Rody, NP</last_name>
      <phone>317-819-1268</phone>
      <email>drody@shideler.com</email>
    </contact>
    <investigator>
      <last_name>Stephen J Shideler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cypress Medical Research Center, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodi Brown, BS, CCRC</last_name>
      <phone>316-425-6333</phone>
      <email>jodi@cypressmrc.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey P Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alissa Prochniak, CCRC</last_name>
      <phone>763-571-4200</phone>
      <email>mcsc@associatedskincare.com</email>
    </contact>
    <investigator>
      <last_name>Steven E Kempers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Dermatology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemary King, PA-C</last_name>
      <phone>314-256-3436</phone>
      <email>kingrm@slu.edu</email>
    </contact>
    <investigator>
      <last_name>Dee Anna Glaser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Bell</last_name>
      <phone>402-697-6599</phone>
      <email>ashleybell@lovelyskin.com</email>
    </contact>
    <investigator>
      <last_name>Joel Schlessigner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Dermatology Group, PC</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanni Villalona</last_name>
      <phone>973-571-2121</phone>
      <phone_ext>2166</phone_ext>
      <email>jvillalona@thedermgroup.com</email>
    </contact>
    <contact_backup>
      <last_name>Taina Negron</last_name>
      <phone>973-571-2121</phone>
      <phone_ext>2166</phone_ext>
      <email>tnegron@thedermgroup.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Nossa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Norton</last_name>
      <phone>503-245-1525</phone>
      <email>brendaormedresearch@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Andrew Blauvelt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies, Inc.</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Scott, CCRC</last_name>
      <phone>979-774-5933</phone>
      <email>jscott@js-studies.com</email>
    </contact>
    <investigator>
      <last_name>Terry M Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Griffith, BS, CCRC</last_name>
      <phone>210-949-0122</phone>
      <email>agriffith@cttexas.com</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Hughes Tichy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center, Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Riley, CCRC</last_name>
      <phone>801-269-0135</phone>
      <email>laura@dermatologyresearch.net</email>
    </contact>
    <contact_backup>
      <last_name>Christine Pyne, CCRC</last_name>
      <phone>801-269-0135</phone>
      <email>christine@dermatologyresearch.net</email>
    </contact_backup>
    <investigator>
      <last_name>Leonard M Swinyer, MD, FAAD, CPI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Franklin, CRC</last_name>
      <phone>757-625-0151</phone>
      <email>lfranklin@vcrinc.org</email>
    </contact>
    <investigator>
      <last_name>David M Pariser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westend Dermatology Associates</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Koliha, RN</last_name>
      <phone>206-315-0391</phone>
      <email>ckoliha@daseattle.com</email>
    </contact>
    <investigator>
      <last_name>Peter Jenkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Clinical Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Cheatham, CCRC</last_name>
      <phone>206-522-3330</phone>
      <phone_ext>129</phone_ext>
      <email>echeatham@seattlewomens.com</email>
    </contact>
    <investigator>
      <last_name>Robin Kroll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lina Lebedinski, CCRC</last_name>
      <phone>509-343-3710</phone>
      <email>lina@premierclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>William P Werschler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
